Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3

Journal of the National Cancer Institute

Volumn 91, Issue 7, 1999, Pages 620-625

  Ma, Jing ^a   Pollak, Michael N ^b   Giovannucci, Edward ^a,c   Chan, June M ^d   Tao, Yuzhen ^b   Hennekens, Charles H ^d   Stampfer, Meir J ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER RISK; COLORECTAL CANCER; DIAGNOSTIC VALUE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0033531765     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.7.620     Document Type: Article

References (44)

1. Cohick WS, Clemmons DR. The insulin-like growth factors. Annu Rev Physiol 1993;55: 131-53.
2. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 1992;65:311-20.
3. LeRoith D, Baserga R, Helman L, Roberts CT Jr. Insulin-like growth factors and cancer. Ann Intern Med 1995;122:54-9.
4. Koenuma M, Yamori T, Tsuruo T. Insulin and insulin-like growth factor 1 stimulate proliferation of metastatic variants of colon carcinoma 26. Jpn J Cancer Res 1989;80:51-8.
5. Pollak MN, Perdue JF, Margolese RG, Baer K, Richard M. Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett 1987;38:223-30.
6. Lambert S, Collette J, Gillis J, Franchimont P, Desaive C, Gol-Winkler R. Tumor IGF-II content in a patient with a colon adenocarcinoma correlates with abnormal expression of the gene. Int J Cancer 1991;48:826-30.
7. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, et al. Gene expression profiles in normal and cancer cells. Science 1997;276:1268-72.
8. Culouscou JM, Remacle-Bonnet M, Garrouste F, Fantini J, Marvaldi J, Pommier G. Production of insulin-like-growth factor II (IGF-II) and different forms of IGF-binding proteins by HT-29 human colon cancer carcinoma cell line. J Cell Physiol 1990;143:405-15.
9. Lahm H, Suardet L, Laurent PL, Fischer JR, Ceyhan A, Givel JC, et al. Growth regulation and co-stimulation of human colorectal cancer cell lines by insulin-like growth factor I, II and transforming growth factor alpha. Br J Cancer 1992;65:341-6.
10. Remacle-Bonnet M, Garrouste F, el Atiq F, Roccabianca M, Marvaldi J, Pommier G. des(1-3)-IGF-I, an insulin-like growth factor analog used to mimic a potential IGF-II autocrine loop, promotes the differentiation of human colon-carcinoma cells. Int J Cancer 1992;52: 910-7.
11. Lahm H, Amstad P, Wyniger J, Yilmaz A, Fischer JR, Schreyer M, et al. Blockade of the insulin-like growth-factor-I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF-II-mediated autocrine loop. Int J Cancer 1994;58:452-9.
12. Brunner JE, Johnson CC, Zafar S, Peterson EL, Brunner JF, Mellinger RC. Colon cancer and polyps in acromegaly: increased risk associated with family history of colon cancer. Clin Endocrinol (Oxf) 1990;32:65-71.
13. Ron E, Gridley G, Hrubec Z, Page W, Arora S, Fraumeni JF Jr. Acromegaly and gastrointestinal cancer [published erratum appears in Cancer 1992;69:549]. Cancer 1991;68:1673-7.
14. Jenkins PJ, Fairclough PD, Richards T, Lowe DG, Monson J, Grossman A, et al. Acromegaly, colonic polyps and carcinoma. Clin Endocrinol (Oxf) 1997;47:17-22.
15. Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med 1997;336: 663-40.
16. Pommier G, Garrouste F, el Atiq F, Marvaldi J, Remacle-Bonnet M. Potential role of IGFBPS in the regulation of the differentiation state of human colonic carcinoma cells. Growth Regul 1993;3:80-2.
17. Michell NP, Dent S, Langman MJ, Eggo MC. Insulin-like growth factor binding proteins as mediators of IGF-I effects on colon cancer cell proliferation. Growth Factors 1997;14:269-77.
18. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997;272: 12181-8.
19. Ranke MB, Elmlinger M. Functional role of insulin-like growth factor binding proteins. Horm Res 1997;48 Suppl 4:9-15.
20. Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 1996;28:619-37.
21. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
22. Pollak M, Costantino J, Polychronakos C, Blauer SA, Guyda H, Redmond C, et al. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 1990;82:1693-7.
23. Huynh H, Yang X, Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 1996;271:1016-21.
24. Singh P, Dai B, Yallampalli U, Lu X, Schroy PC. Proliferation and differentiation of a human colon cancer cell line (CaCo2) is associated with statistically significant changes in the expression and secretion of insulin-like growth factor (IGF) IGF-II and IGF binding protein-4: role of IGF-II. Endocrinology 1996;137: 1764-74.
25. Singh P, Dai B, Yallampalli U, Xu Z. Expression of IGF-II and IGF-binding proteins by colon cancer cells in relation to growth response to IGFs. Am J Physiol 1994;267(4 Pt 1):G608-17.
26. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson CH, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
27. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351: 1393-6.
28. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334:1145-9.
29. SAS Institute I. SAS/STATR User's Guide Version 6. Cary (NC): SAS Institute Inc; 1989.
30. Juul A, Dalgaard P, Blum WF, Bang P, Hall K, Michaelson KF, et al. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 1995;80:2534-42.
31. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993;85:1220-4.
32. Guler HP, Zapf J, Schmid C, Froesch ER. Insulin-like growth factors I and II in healthy men. Estimations of half-lives and production rates. Acta Endocrinol (Copenh) 1989;121: 753-8.
33. Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jorgensen K, et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994;78:744-52.
34. Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study [published erratum appears in Am J Epidemiol 1997;146:357]. Am J Epidemiol 1997; 145:970-6.
35. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
36. Cohen SM, Ellwein LB. Cell proliferation in carcinogenesis. Science 1990;249:1007-11.
37. Warren RS, Yuan H, Matli MR, Ferrara N, Donner DB. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chem 1996;271: 29483-8.
38. Buckbinder L, Talbott R, Velasco-Miguel S, Takenada I, Faha B, Seizinger BR, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995;377: 646-9.
39. Cats A, Dullaart R, Kleibeuker JH, Kuipers F, Sluiter WJ, Hardonk MJ, et al. Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Res 1996;56: 523-6.
40. Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxf) 1994;41:85-93.
41. Glass AR, Kikendall JW, Sobin LH, Bowen PE. Serum concentrations of insulin-like growth factor 1 in colonic neoplasia. Acta Oncol 1994;33:70-1.
42. el Atiq F, Garrouste F, Remacle-Bonnet M, Sastre B, Pommier G. Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer 1994;57: 491-7.
43. Gelato MC. Aging and immune function: a possible role for growth hormone. Horm Res 1996;45:46-9.
44. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990;323:1-6.